Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
Latin Times on MSN2h
UnitedHealth Is Price Gouging Cancer Patients by Overcharging 'Thousands of Percent' for Live-Saving Meds, Pocketing Extra Billions: FedsThe UnitedHealth Group is overcharging patients for necessary life-saving drugs as a result of price gouging that increases ...
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...
The Massachusetts Democrat is working with a Missouri Republican, and House members from each party, to press the FTC to ...
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback